© Springer-Verlag Berlin Heidelberg 2015Nima Rezaei (ed.)Cancer Immunology10.1007/978-3-662-46410-6_23 23. Immunology and Immunotherapy of Breast Cancer John Stagg1 and Sherene Loi2 (1) Centre de Recherche du Centre Hospitalier de l’Université de Montréal, 900 St-Denis Street Montreal, Montreal,…
29. Bennaceur K, Chapman JA, Touraine J-l, Portoukalian J. RETRACTED: immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochi Biophys Acta (BBA)-Rev Cancer. 2009;1795(1):16–24. 30. Kalluri…
4. Chakrabarti A, Verbridge S, Stroock AD, Fischbach C, Varner JD. Multiscale models of breast cancer progression. Ann Biomed Eng. 2012;40:2488–500.PubMed 5. Taddei ML, Giannoni E, Comito G, Chiarugi P….
15. Lamm DL, Bluemenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma…
TLR Ligand/agonist Potential therapeutic agents TLR1 Triacylated lipoproteins, lipoteichoic acid, peptidoglycans PAM3CSK4 [93] BCG TLR2 Endogenous DAMPs (HSP, HMGB1, uric acid, fibronectin, ECM proteins) [5] PAM3CSK4 [94–96] BCG [97] HSP60…
43. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001;106(3):271–4.PubMed 44. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell…
Approach of immunotherapy Model Reference Alpha-galactosylceramide-pulsed antigen-presenting cells Human [93] Anti-CD3/CD28 monoclonal antibody Human [94] CSC-based vaccination In vivo, in vitro [89, 95] DNA-Hsp65 (a DNA vaccine) Human [96] Epstein-Barr…
Antigen Location Expression in tumor Prevalence (%) Description CEA Cell surface (GPI-linked) Overexpressed 30–100 Glycoprotein, normally expressed only on oncofetal tissues. Functions as cell-adhesion molecule. First tumor antigen to be…
Regimen Disease status n ORR CR Survival Reference R-GEM High-grade B-NHL (elderly: 64–78 years) 7 (1 previously untreated) 71 % 29 % PFS:10 m [344] OS:11 m R-GEMOX Aggressive NHL…
Treatment Disease of EGC No. of enrolled patients Clinical response (CR/PR) Median survival (mos) References Cetuximab + FOLFOX/RT + surgery E, ESCC 41 8/12 17 [43] Cetuximab + cisplatin/docetaxel/RT +…
